269 related articles for article (PubMed ID: 18619902)
1. Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment.
Svae TE; Neisser-Svae A; Bailey A; Reichl H; Biesert L; Schmidt T; Heger A; Römisch J
Transfus Apher Sci; 2008 Aug; 39(1):59-67. PubMed ID: 18619902
[TBL] [Abstract][Full Text] [Related]
2. Pathogen reduction of blood components.
Solheim BG
Transfus Apher Sci; 2008 Aug; 39(1):75-82. PubMed ID: 18602343
[TBL] [Abstract][Full Text] [Related]
3. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products.
Turner ML; Ludlam CA
Br J Haematol; 2009 Jan; 144(1):14-23. PubMed ID: 18950452
[TBL] [Abstract][Full Text] [Related]
4. Current strategies to prevent transmission of prions by human plasma derivatives.
Burnouf T; Padilla A
Transfus Clin Biol; 2006 Nov; 13(5):320-8. PubMed ID: 17254822
[TBL] [Abstract][Full Text] [Related]
5. Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: precautionary measures and efficacy of manufacturing processes in prion removal.
Flan B; Arrabal S
Transfus Clin Biol; 2007 May; 14(1):51-62. PubMed ID: 17540602
[TBL] [Abstract][Full Text] [Related]
6. Update on pathogen reduction technology for therapeutic plasma: an overview.
Solheim BG; Seghatchian J
Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
[TBL] [Abstract][Full Text] [Related]
7. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products.
Ludlam CA; Turner ML
Br J Haematol; 2006 Jan; 132(1):13-24. PubMed ID: 16371015
[TBL] [Abstract][Full Text] [Related]
8. An overview of prion biology and the role of blood filtration in reducing the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease.
Cervia JS; Sowemimo-Coker SO; Ortolano GA; Wilkins K; Schaffer J; Wortham ST
Transfus Med Rev; 2006 Jul; 20(3):190-206. PubMed ID: 16787827
[TBL] [Abstract][Full Text] [Related]
9. Balancing evidence and public opinion in health technology assessments: the case of leukoreduction.
Cleemput I; Leys M; Ramaekers D; Bonneux L
Int J Technol Assess Health Care; 2006; 22(4):403-7. PubMed ID: 16984672
[TBL] [Abstract][Full Text] [Related]
10. Current opinions on the role of pathogen reduction technology in improving the viral safety of blood and derivatives.
Seghatchian J
Transfus Apher Sci; 2008 Aug; 39(1):49-50. PubMed ID: 18617442
[No Abstract] [Full Text] [Related]
11. Variant Creutzfeldt-Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty.
Farrugia A; Ironside JW; Giangrande P
Vox Sang; 2005 Nov; 89(4):186-92. PubMed ID: 16262750
[TBL] [Abstract][Full Text] [Related]
12. The in vitro bioassay systems for the amplification and detection of abnormal prion PrP(Sc) in blood and tissues.
Zhang W; Wu J; Li Y; Carke RC; Wong T
Transfus Med Rev; 2008 Jul; 22(3):234-42. PubMed ID: 18572098
[TBL] [Abstract][Full Text] [Related]
13. The six questions of pathogen reduction technology: an overview of current opinions.
Solheim BG; Seghatchian J
Transfus Apher Sci; 2008 Aug; 39(1):51-7. PubMed ID: 18614401
[TBL] [Abstract][Full Text] [Related]
14. ['Variant of Creutzfeldt-Jacob disease and blood transfusion'; report of the Dutch Health Council].
van Aken WG
Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1444-7. PubMed ID: 11503311
[TBL] [Abstract][Full Text] [Related]
15. International views on universal leucodepletion: the perspective in NBS, England.
Wallington T
Transfus Sci; 1998 Dec; 19(4):347-8. PubMed ID: 10351150
[No Abstract] [Full Text] [Related]
16. [Aspects of the risks associated with vCJK from plasma derivatives from human plasma].
Burger R; Offergeld R
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Jun; 52(6):648-9. PubMed ID: 19557456
[No Abstract] [Full Text] [Related]
17. Creutzfeldt-Jakob disease: recommendations for disinfection and sterilization.
Rutala WA; Weber DJ
Clin Infect Dis; 2001 May; 32(9):1348-56. PubMed ID: 11303271
[TBL] [Abstract][Full Text] [Related]
18. Creutzfeldt-Jakob disease: current U.S. policy to further reduce the possible risk of transmission by transfusion.
Menache D; O'Malley JP
Biologicals; 1996 Sep; 24(3):277-83. PubMed ID: 8978926
[TBL] [Abstract][Full Text] [Related]
19. Creutzfeldt-Jakob disease: reflections on the risk from blood product therapy.
Brown P
Haemophilia; 2007 Dec; 13 Suppl 5():33-40. PubMed ID: 18078395
[TBL] [Abstract][Full Text] [Related]
20. Clearance of prions during plasma protein manufacture.
Burdick MD; Pifat DY; Petteway SR; Cai K
Transfus Med Rev; 2006 Jan; 20(1):57-62. PubMed ID: 16373188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
